Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus DIFLUPREDNATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus DIFLUPREDNATE.
CAPEX vs DIFLUPREDNATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Difluprednate is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory mediators.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply thin film to affected area twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Clinical Note
moderateDifluprednate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Gatifloxacin."
Clinical Note
moderateDifluprednate + Rosoxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Rosoxacin."
Clinical Note
moderateDifluprednate + Levofloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life approximately 2–4 hours; clinically, duration of action may extend due to receptor binding.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily renal (65–75% as metabolites), with biliary/fecal excretion accounting for 15–25%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
Difluprednate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Trovafloxacin."